<?xml version='1.0' encoding='utf-8'?>
<document id="31177048"><sentence text="Liquid chromatography tandem mass spectrometry for the simultaneous determination of metformin and pioglitazone in rat plasma: Application to pharmacokinetic and drug-drug interaction studies."><entity charOffset="85-94" id="DDI-PubMed.31177048.s1.e0" text="metformin" /><entity charOffset="99-111" id="DDI-PubMed.31177048.s1.e1" text="pioglitazone" /><pair ddi="false" e1="DDI-PubMed.31177048.s1.e0" e2="DDI-PubMed.31177048.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31177048.s1.e0" e2="DDI-PubMed.31177048.s1.e1" /></sentence><sentence text="Failure to attain and sustain long term glycemic control is an ongoing challenge in diabetes therapy" /><sentence text=" The trend to use a combined therapy and the risk of drug-drug interaction (DDI) are elevated and thus the need for sensitive analytical methods is of great significance" /><sentence text=" Herein, a simple, robust, and sensitive reverse phase high performance liquid chromatography-electrospray ionization-tandem mass spectrometry (ESI-MS/MS) method for simultaneous determination of metformin (MET) and pioglitazone (PGT) in rat plasma using canagliflozin (CAN) as internal standards (IS) was developed and fully validated"><entity charOffset="196-205" id="DDI-PubMed.31177048.s4.e0" text="metformin" /><entity charOffset="207-210" id="DDI-PubMed.31177048.s4.e1" text="MET" /><entity charOffset="216-228" id="DDI-PubMed.31177048.s4.e2" text="pioglitazone" /><entity charOffset="230-233" id="DDI-PubMed.31177048.s4.e3" text="PGT" /><entity charOffset="255-268" id="DDI-PubMed.31177048.s4.e4" text="canagliflozin" /><entity charOffset="270-273" id="DDI-PubMed.31177048.s4.e5" text="CAN" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e0" e2="DDI-PubMed.31177048.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e0" e2="DDI-PubMed.31177048.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e0" e2="DDI-PubMed.31177048.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e0" e2="DDI-PubMed.31177048.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e0" e2="DDI-PubMed.31177048.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e0" e2="DDI-PubMed.31177048.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e1" e2="DDI-PubMed.31177048.s4.e1" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e1" e2="DDI-PubMed.31177048.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e1" e2="DDI-PubMed.31177048.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e1" e2="DDI-PubMed.31177048.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e1" e2="DDI-PubMed.31177048.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e2" e2="DDI-PubMed.31177048.s4.e2" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e2" e2="DDI-PubMed.31177048.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e2" e2="DDI-PubMed.31177048.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e2" e2="DDI-PubMed.31177048.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e3" e2="DDI-PubMed.31177048.s4.e3" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e3" e2="DDI-PubMed.31177048.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e3" e2="DDI-PubMed.31177048.s4.e5" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e4" e2="DDI-PubMed.31177048.s4.e4" /><pair ddi="false" e1="DDI-PubMed.31177048.s4.e4" e2="DDI-PubMed.31177048.s4.e5" /></sentence><sentence text=" Prior Chromatographic separation on an Agilent Eclipse Plus C18 (4" /><sentence text="6 × 100 mm, 3" /><sentence text="5 μm) using gradient mobile phase system consisting of ammonium formate pH 4"><entity charOffset="55-71" id="DDI-PubMed.31177048.s7.e0" text="ammonium formate" /></sentence><sentence text="5 and acetonitrile at a flow rate of 0"><entity charOffset="6-18" id="DDI-PubMed.31177048.s8.e0" text="acetonitrile" /></sentence><sentence text="5 mL min-1, within a run time of 14 min, the antidiabetic drugs were extracted from rat plasma using acetonitrile-induced protein precipitation technique"><entity charOffset="101-113" id="DDI-PubMed.31177048.s9.e0" text="acetonitrile" /></sentence><sentence text=" Multiple reaction monitoring in positive ion mode was used for quantitation of precursor to production at m/z 130" /><sentence text="1 → 71" /><sentence text="0 &amp; 60 for MET, 357"><entity charOffset="11-22" id="DDI-PubMed.31177048.s12.e0" text="MET" /></sentence><sentence text="2 → 134" /><sentence text="2 for PGT, and 462"><entity charOffset="6-8" id="DDI-PubMed.31177048.s14.e0" text="PGT" /></sentence><sentence text="16 → 191" /><sentence text="1 for CAN"><entity charOffset="6-8" id="DDI-PubMed.31177048.s16.e0" text="CAN" /></sentence><sentence text=" Method linearity was obeyed in the range of 1 to 5000 and 1 to 2500 ng mL-1 for MET and PGT, respectively"><entity charOffset="81-83" id="DDI-PubMed.31177048.s17.e0" text="MET" /><entity charOffset="89-91" id="DDI-PubMed.31177048.s17.e1" text="PGT" /><pair ddi="false" e1="DDI-PubMed.31177048.s17.e0" e2="DDI-PubMed.31177048.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31177048.s17.e0" e2="DDI-PubMed.31177048.s17.e1" /></sentence><sentence text=" The developed method was validated in terms of accuracy, precision, selectivity, recovery, matrix effects, and stability as per US-FDA bioanalytical guidelines and successfully applied to clinical pharmacokinetic and DDI studies with a single oral administration of target compounds" /><sentence text=" The peak plasma concentrations (Cmax) and area under the concentration-time curve (AUC) of MET was significantly influenced by the concomitant administration of PGT at equal concentration and vice versa"><entity charOffset="92-94" id="DDI-PubMed.31177048.s19.e0" text="MET" /><entity charOffset="162-164" id="DDI-PubMed.31177048.s19.e1" text="PGT" /><pair ddi="false" e1="DDI-PubMed.31177048.s19.e0" e2="DDI-PubMed.31177048.s19.e0" /><pair ddi="false" e1="DDI-PubMed.31177048.s19.e0" e2="DDI-PubMed.31177048.s19.e1" /></sentence><sentence text=" PGT affected the absorption and elimination rate of MET via inhibition of organic cationic transporter (OCT)"><entity charOffset="53-55" id="DDI-PubMed.31177048.s20.e0" text="MET" /><entity charOffset="1-3" id="DDI-PubMed.31177048.s20.e1" text="PGT" /><pair ddi="false" e1="DDI-PubMed.31177048.s20.e1" e2="DDI-PubMed.31177048.s20.e1" /><pair ddi="false" e1="DDI-PubMed.31177048.s20.e1" e2="DDI-PubMed.31177048.s20.e0" /></sentence><sentence text=" Molecular modeling study revealed the significant interaction of PGT with OCT"><entity charOffset="66-68" id="DDI-PubMed.31177048.s21.e0" text="PGT" /></sentence><sentence text=" A potential DDI in type 2 diabetic patient receiving chronic treatment with MET and PGT deserves further attention and study to improve drug therapy and prevent adverse effects"><entity charOffset="77-79" id="DDI-PubMed.31177048.s22.e0" text="MET" /><entity charOffset="85-87" id="DDI-PubMed.31177048.s22.e1" text="PGT" /><pair ddi="false" e1="DDI-PubMed.31177048.s22.e0" e2="DDI-PubMed.31177048.s22.e0" /><pair ddi="false" e1="DDI-PubMed.31177048.s22.e0" e2="DDI-PubMed.31177048.s22.e1" /></sentence><sentence text="" /></document>